Skip to main content
SpringerLink
Log in

Inflammatory Disorders: Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis, Lupus Erythematosus, Dermatomyositis, and Scleroderma

  • Chapter
  • First Online:
Ethnic Skin and Hair and Other Cultural Considerations

Part of the book series: Updates in Clinical Dermatology ((UCD))

Abstract

Common inflammatory disorders of the skin may have unique morphologies and clinical or therapeutic considerations in individuals with skin of color. These include acne vulgaris, atopic dermatitis, and seborrheic dermatitis. In addition, several multi-system inflammatory disorders with cutaneous manifestations – such as lupus erythematosus, dermatomyositis, and scleroderma – are more prevalent in populations of African ancestry. Recognizing racial/ethnic variations in the clinical presentation and approach to treatment of these disorders is key to optimizing patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56–9.

    Article  PubMed  Google Scholar 

  2. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387–94.

    PubMed  Google Scholar 

  3. Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol: JDD. 2012;11(4):466–73.

    PubMed  Google Scholar 

  4. Lawson CN, Callender VD. Acne and rosacea. In: Vashi NA, Maibach HI, editors. Dermatoanthropology of ethnic skin and hair. Cham: Springer International Publishing; 2017. p. 103–28.

    Chapter  Google Scholar 

  5. Callender VD, Alexis AF, Daniels SR, Kawata AK, Burk CT, Wilcox TK, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19–31.

    PubMed  PubMed Central  Google Scholar 

  6. Rendon MI, Rodriguez DA, Kawata AK, Degboe AN, Wilcox TK, Burk CT, et al. Acne treatment patterns, expectations, and satisfaction among adult females of different races/ethnicities. Clin Cosmet Investig Dermatol. 2015;8:231–8.

    PubMed  PubMed Central  Google Scholar 

  7. Abad-Casintahan F, Chow SK, Goh CL, Kubba R, Hayashi N, Noppakun N, et al. Frequency and characteristics of acne-related post-inflammatory hyperpigmentation. J Dermatol. 2016;43(7):826–8.

    Article  PubMed  Google Scholar 

  8. Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol: JEADV. 2011;25(9):1054–60.

    Article  CAS  PubMed  Google Scholar 

  9. Gorelick J, Daniels SR, Kawata AK, Degboe A, Wilcox TK, Burk CT, et al. Acne-related quality of life among female adults of different races/ethnicities. J Dermatol Nurses Assoc. 2015;7(3):154–62.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2):S1–S23.e1.

    Article  PubMed  Google Scholar 

  11. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005;76(2):145–51.

    PubMed  Google Scholar 

  12. Thielitz A, Helmdach M, Ropke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001;145(1):19–27.

    Article  CAS  PubMed  Google Scholar 

  13. Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther. 2017;7(3):293–304.

    Article  Google Scholar 

  14. Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol: JDD. 2010;9(5):549–58.

    PubMed  Google Scholar 

  15. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol: JDD. 2008;7(6 Suppl):s3–10.

    PubMed  Google Scholar 

  16. Tu P, Li GQ, Zhu XJ, Zheng J, Wong WZ. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol: JEADV. 2001;15(Suppl 3):31–6.

    Article  PubMed  Google Scholar 

  17. Alexis AF, Johnson LA, Kerrouche N, Callender VD. A subgroup analysis to evaluate the efficacy and safety of adapalene-benzoyl peroxide topical gel in black subjects with moderate acne. J Drugs Dermatol: JDD. 2014;13(2):170–4.

    CAS  PubMed  Google Scholar 

  18. Zeichner J. Strategies to minimize irritation and potential iatrogenic post-inflammatory pigmentation when treating acne patients with skin of color. J Drugs Dermatol: JDD. 2011;10(12 Suppl):s25–6.

    PubMed  Google Scholar 

  19. Kawashima M, Sato S, Furukawa F, Matsunaga K, Akamatsu H, Igarashi A, et al. Twelve-week, multicenter, placebo-controlled, randomized, double-blind, parallel-group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. J Dermatol. 2017;44(7):774–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25(10):664–7.

    Article  PubMed  Google Scholar 

  21. Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol: JDD. 2011;10(6):586–90.

    CAS  PubMed  Google Scholar 

  22. Woolery-Lloyd HC, Keri J, Doig S. Retinoids and azelaic acid to treat acne and hyperpigmentation in skin of color. J Drugs Dermatol: JDD. 2013;12(4):434–7.

    CAS  PubMed  Google Scholar 

  23. Alexis AF, Burgess C, Callender VD, Herzog JL, Roberts WE, Schweiger ES, et al. The efficacy and safety of topical dapsone gel, 5% for the treatment of acne vulgaris in adult females with skin of color. J Drugs Dermatol: JDD. 2016;15(2):197–204.

    CAS  PubMed  Google Scholar 

  24. Taylor SC, Cook-Bolden FE, McMichael A, Downie JB, Rodriguez DA, Alexis AF, et al. Efficacy, safety, and tolerability of topical dapsone gel, 7.5% for treatment of acne vulgaris by Fitzpatrick skin phototype. J Drugs Dermatol: JDD. 2018;17(2):160–7.

    PubMed  Google Scholar 

  25. Alexis AF. Acne vulgaris in skin of color: understanding nuances and optimizing treatment outcomes. J Drugs Dermatol: JDD. 2014;13(6):s61–5.

    PubMed  Google Scholar 

  26. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3(4):24–38.

    PubMed  PubMed Central  Google Scholar 

  27. Kelly AP, Sampson DD. Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin. J Natl Med Assoc. 1987;79(12):1266–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Garg VK, Sinha S, Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatol Surg. 2009;35(1):59–65.

    CAS  PubMed  Google Scholar 

  29. Fu T, Keiser E, Linos E, Rotatori RM, Sainani K, Lingala B, et al. Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study. Pediatr Dermatol. 2014;31(1):21–6.

    Article  PubMed  Google Scholar 

  30. Williams HC, Pembroke AC, Forsdyke H, Boodoo G, Hay R, Burney P. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol. 1995;32(2):212–7.

    Article  CAS  PubMed  Google Scholar 

  31. Mar A, Tam M, Jolley D, Marks R. The cumulative incidence of atopic dermatitis in the first 12 months among Chinese, Vietnamese, and Caucasian infants born in Melbourne, Australia. J Am Acad Dermatol. 1999;40(4):597–602.

    Article  CAS  PubMed  Google Scholar 

  32. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–8.e23.

    Article  PubMed  Google Scholar 

  33. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Li K, Oh WJ, Park KY, Kim KH, Seo SJ. FLG mutations in the East Asian atopic dermatitis patients: genetic and clinical implication. Exp Dermatol. 2016;25(10):816–8.

    Article  CAS  PubMed  Google Scholar 

  35. Margolis DJ, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Campbell LE, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol. 2012;130(4):912–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Margolis DJ, Gupta J, Apter AJ, Ganguly T, Hoffstad O, Papadopoulos M, et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African Americans. J Allergy Clin Immunol. 2014;133(3):784–9.

    Article  CAS  PubMed  Google Scholar 

  37. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–57.

    Article  PubMed  Google Scholar 

  38. Bolognia J, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012.

    Google Scholar 

  39. Xu F, Yan S, Zheng Q, Li F, Chai W, Wu M, et al. Residential risk factors for atopic dermatitis in 3- to 6-year old children: a cross-sectional study in Shanghai, China. Int J Environ Res Public Health. 2016;13(6):537.

    Article  PubMed Central  Google Scholar 

  40. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–30.e6.

    Article  PubMed  Google Scholar 

  41. Sasaki T, Furusyo N, Shiohama A, Takeuchi S, Nakahara T, Uchi H, et al. Filaggrin loss-of-function mutations are not a predisposing factor for atopic dermatitis in an Ishigaki Island under subtropical climate. J Dermatol Sci. 2014;76(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  42. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–64.

    Article  CAS  PubMed  Google Scholar 

  43. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118–27.

    Article  PubMed  Google Scholar 

  44. Syed ZU, Hamzavi IH. Photomedicine and phototherapy considerations for patients with skin of color. Photodermatol Photoimmunol Photomed. 2011;27(1):10–6.

    Article  PubMed  Google Scholar 

  45. Love PB. Inflammatory disorders. In: Vashi NA, Maibach HI, editors. Dermatoanthropology of ethnic skin and hair. Cham: Springer International Publishing; 2017. p. 129–41.

    Chapter  Google Scholar 

  46. Hon KL, Tsang YC, Lee VW, Pong NH, Ha G, Lee ST, et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema: a randomized, placebo-controlled cross-over trial. J Dermatolog Treat. 2016;27(2):156–62.

    Article  CAS  PubMed  Google Scholar 

  47. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123(5):e808–14.

    Article  PubMed  Google Scholar 

  48. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185–90.

    PubMed  Google Scholar 

  49. Ostlere LS, Taylor CR, Harris DW, Rustin MH, Wright S, Johnson M. Skin surface lipids in HIV-positive patients with and without seborrheic dermatitis. Int J Dermatol. 1996;35(4):276–9.

    Article  CAS  PubMed  Google Scholar 

  50. Taylor SC. Treatments for skin of color. Edinburgh: Saunders/Elsevier; 2011. Available from: http://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20090395422; http://www.clinicalkey.com.au/dura/browse/bookChapter/3-s2.0-C20090395422; http://site.ebrary.com/id/10493316; http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=444950; http://www.myilibrary.com?id=754895; https://www.clinicalkey.com.au/dura/browse/bookChapter/3-s2.0-C20090395422; http://ezsecureaccess.balamand.edu.lb/login?url=https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20090395422; https://nls.ldls.org.uk/welcome.html?ark:/81055/vdc_100052715963.0x000001.

  51. Friedmann DP, Mishra V, Batty T. Progressive facial papules in an African-American patient: an atypical presentation of seborrheic dermatitis. J Clin Aesthet Dermatol. 2018;11(7):44–5.

    PubMed  PubMed Central  Google Scholar 

  52. Wannanukul S, Chiabunkana J. Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis. J Med Assoc Thail = Chotmaihet thangphaet. 2004;87(Suppl 2):S68–71.

    Google Scholar 

  53. Rodney IJ, Onwudiwe OC, Callender VD, Halder RM. Hair and scalp disorders in ethnic populations. J Drugs Dermatol: JDD. 2013;12(4):420–7.

    PubMed  Google Scholar 

  54. Milani M, Antonio Di Molfetta S, Gramazio R, Fiorella C, Frisario C, Fuzio E, et al. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr Med Res Opin. 2003;19(4):342–5.

    Article  CAS  PubMed  Google Scholar 

  55. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol. 2006;54(6):1083–8.

    Article  PubMed  Google Scholar 

  56. Stratigos JD, Antoniou C, Katsambas A, Bohler K, Fritsch P, Schmolz A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J Am Acad Dermatol. 1988;19(5 Pt 1):850–3.

    Article  CAS  PubMed  Google Scholar 

  57. Drenkard C, Parker S, Aspey LD, Gordon C, Helmick CG, Bao G, et al. Racial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the Southeastern United States: the Georgia Lupus Registry. Arthritis Care Res. 2019;71(1):95–103.

    Article  CAS  Google Scholar 

  58. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis. 1994;53(10):675–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Jarrett P, Thornley S, Scragg R. Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand. Lupus. 2016;25(13):1497–502.

    Article  CAS  PubMed  Google Scholar 

  60. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75(1):136–41.

    Article  PubMed  Google Scholar 

  61. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 2009;10(5):373–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Singh B, Walter S, Callaghan DJ, Paek J, Lam C. Autoimmune and connective tissue disease in skin of color. In: Vashi NA, Maibach HI, editors. Dermatoanthropology of ethnic skin and hair. Cham: Springer International Publishing; 2017. p. 161–95.

    Chapter  Google Scholar 

  63. Schultz HY, Dutz JP, Furukawa F, Goodfield MJ, Kuhn A, Lee LA, et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J Invest Dermatol. 2015;135(1):7–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Molomo EM, Bouckaert M, Khammissa RA, Motswaledi HM, Lemmer J, Feller L. Discoid lupus erythematosus-related squamous cell carcinoma of the lip in an HIV-seropositive black male. J Cancer Res Ther. 2015;11(4):1036.

    Article  CAS  PubMed  Google Scholar 

  65. Fernandes MS, Girisha BS, Viswanathan N, Sripathi H, Noronha TM. Discoid lupus erythematosus with squamous cell carcinoma: a case report and review of the literature in Indian patients. Lupus. 2015;24(14):1562–6.

    Article  CAS  PubMed  Google Scholar 

  66. Pons-Estel GJ, Aspey LD, Bao G, Pons-Estel BA, Wojdyla D, Saurit V, et al. Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus. 2017;26(1):73–83.

    Article  CAS  PubMed  Google Scholar 

  67. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465–72.

    CAS  PubMed  Google Scholar 

  68. Magro CM, Crowson AN. The cutaneous pathology associated with seropositivity for antibodies to SSA (Ro): a clinicopathologic study of 23 adult patients without subacute cutaneous lupus erythematosus. Am J Dermatopathol. 1999;21(2):129–37.

    Article  CAS  PubMed  Google Scholar 

  69. Lee A, Batra P, Furer V, Cheung W, Wang N, Franks A Jr. Rowell syndrome (systemic lupus erythematosus + erythema multiforme). Dermatol Online J. 2009;15(8):1.

    Article  PubMed  Google Scholar 

  70. Petit A, Dadzie OE. Multisystemic diseases and ethnicity: a focus on lupus erythematosus, systemic sclerosis, sarcoidosis and Behcet disease. Br J Dermatol. 2013;169(Suppl 3):1–10.

    Article  PubMed  Google Scholar 

  71. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

    Article  CAS  PubMed  Google Scholar 

  72. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus. 1999;8(3):197–209.

    Article  CAS  PubMed  Google Scholar 

  73. Uribe AG, McGwin G Jr, Reveille JD, Alarcon GS. What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading? Autoimmun Rev. 2004;3(4):321–9.

    Article  PubMed  Google Scholar 

  74. Lim SS, Drenkard C. Epidemiology of lupus: an update. Curr Opin Rheumatol. 2015;27(5):427–32.

    Article  PubMed  Google Scholar 

  75. Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 2006;54(9):2963–9.

    Article  PubMed  Google Scholar 

  76. Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748–62.

    Article  PubMed  Google Scholar 

  77. Avgerinou G, Papafragkaki DK, Nasiopoulou A, Arapaki A, Katsambas A, Stavropoulos PG. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol: JEADV. 2012;26(6):762–7.

    Article  CAS  PubMed  Google Scholar 

  78. Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol. 2018;30(3):249–55.

    Article  CAS  PubMed  Google Scholar 

  79. Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus. 2015;24(6):536–45.

    Article  CAS  PubMed  Google Scholar 

  80. Tayer-Shifman OE, Rosen CF, Wakani L, Touma Z. Novel biological therapeutic approaches to cutaneous lupus erythematosus. Expert Opin Biol Ther. 2018;18(10):1041–7.

    Article  CAS  PubMed  Google Scholar 

  81. BENLYSTA [package insert]. Research Triangle Park: GlaxoSmithKline; 2018.

    Google Scholar 

  82. Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016;25(8):830–7.

    Article  CAS  PubMed  Google Scholar 

  83. Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816–28.

    Article  PubMed  Google Scholar 

  84. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):28.

    Article  PubMed  Google Scholar 

  85. Werth VP, Callen JP, Ang G, Sullivan KE. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol. 2002;119(3):617–20.

    Article  CAS  PubMed  Google Scholar 

  86. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.

    Article  CAS  PubMed  Google Scholar 

  87. Peng JC, Sheen TS, Hsu MM. Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg. 1995;121(11):1298–301.

    Article  CAS  PubMed  Google Scholar 

  88. Tersiguel AC, Longueville C, Beltan E, Vincent T, Tressieres B, Cordel N. Prevalence of cancer in the Afro-Caribbean population presenting dermatomyositis and anti-synthetase syndrome: a preliminary study conducted at Pointe-a-Pitre University Hospital, 2000–2012. Ann Dermatol Venereol. 2014;141(10):575–80.

    Article  PubMed  Google Scholar 

  89. Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;14(4):291–313.

    Article  PubMed  Google Scholar 

  90. Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol. 2002;138(1):114–6.

    Article  PubMed  Google Scholar 

  91. Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int. 2016;36(7):935–43.

    Article  CAS  PubMed  Google Scholar 

  92. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11:223.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford, England). 2017;56(6):999–1007.

    Article  CAS  Google Scholar 

  94. Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363–73.

    Article  PubMed  Google Scholar 

  95. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95–102.

    Article  CAS  PubMed  Google Scholar 

  96. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62(10):1496–501.

    Article  Google Scholar 

  97. Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev. 2018;1:Cd010908.

    PubMed  Google Scholar 

  98. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004;15(1):35–9.

    Article  CAS  PubMed  Google Scholar 

  99. Ang G, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141(7):855–9.

    Article  CAS  PubMed  Google Scholar 

  100. Kurtzman DB, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–5.

    Article  PubMed  Google Scholar 

  101. Gutierrez A Jr, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther. 2012;25(2):195–206.

    Article  PubMed  Google Scholar 

  102. Welborn MC, Gottschalk H, Bindra R. Juvenile dermatomyositis: a case of calcinosis cutis of the elbow and review of the literature. J Pediatr Orthop. 2015;35(5):e43–6.

    Article  PubMed  Google Scholar 

  103. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011;65(5):925–41.

    Article  CAS  PubMed  Google Scholar 

  105. Jacobe HT, Cayce R, Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I–V. Br J Dermatol. 2008;159(3):691–6.

    Article  CAS  PubMed  Google Scholar 

  106. Kroft EBM, Groeneveld TJ, Seyger MMB, Jong EMGJ. Efficacy of topical tacrolimus 0.1% in active plaque morphea. Am J Clin Dermatol. 2009;10(3):181–7.

    Article  PubMed  Google Scholar 

  107. Campione E, Paternò EJ, Diluvio L, Orlandi A, Bianchi L, Chimenti S. Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness. J Dermatol Treat. 2009;20(1):10–3.

    Article  CAS  Google Scholar 

  108. Silver RM, Bogatkevich G, Tourkina E, Nietert PJ, Hoffman S. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol. 2012;24(6):642–8.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine. 2013;92(4):191–205.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Satoh M, Krzyszczak ME, Li Y, Ceribelli A, Ross SJ, Chan EK, et al. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study. Arthritis Res Ther. 2011;13(3):R73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Blanco I, Mathai S, Shafiq M, Boyce D, Kolb TM, Chami H, et al. Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine. 2014;93(5):177–85.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64(9):2986–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30(5):332–46.

    Article  CAS  PubMed  Google Scholar 

  114. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol. 2013;32(5):617–21.

    Article  CAS  PubMed  Google Scholar 

  115. Pope JE. New classification criteria for systemic sclerosis (scleroderma). Rheum Dis Clin N Am. 2015;41(3):383–98.

    Article  Google Scholar 

  116. Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):432–7.

    Article  PubMed  Google Scholar 

  117. Sinnathurai P, Schrieber L. Treatment of Raynaud phenomenon in systemic sclerosis. Intern Med J. 2013;43(5):476–83.

    Article  CAS  PubMed  Google Scholar 

  118. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60(3):870–7.

    Article  CAS  PubMed  Google Scholar 

  119. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology. 2009;48(12):1595–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai Morningside and Mount Sinai West, Department of Dermatology, Mount Sinai Doctors, New York, NY, USA

    Andrew F. Alexis

  2. Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, NY, USA

    Whitney A. Talbott

Authors
  1. Andrew F. Alexis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Whitney A. Talbott
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, Howard University Hospital, Washington, DC, USA

    Becky S. Li

  2. Department of Dermatology, University of California San Francisco, San Francisco, CA, USA

    Howard I. Maibach

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Alexis, A.F., Talbott, W.A. (2021). Inflammatory Disorders: Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis, Lupus Erythematosus, Dermatomyositis, and Scleroderma. In: Li, B.S., Maibach, H.I. (eds) Ethnic Skin and Hair and Other Cultural Considerations. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-64830-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-64830-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-64829-9

  • Online ISBN: 978-3-030-64830-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation